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Abstract: Analysis of T cell subsets in the spleen during graft-versus-host (GVH) reactions in a fully 
allogeneic mouse strain combination demonstrated that first CD4+ T cells become activated, and initiate 
the GVH reaction. Subsequently, CD8+ T cells become involved. Here we show that anti-CD8 treatment 
on day +3 resulted in a significant increase in survival, while early treatment (day -1 or day +1) did not. 
Acute GVH reactions were induced (day 0) in lethally irradiated (C57BLI6 x CBA/J)FI (H-2ti) mice by 
in~venous injection of BALBlc (H-2d) spleen and lymph node cells (3.6 x IO’) within 24 h after 
irradiation. Mice were treated intraperitoneally with a single optimally depleting dose of rat anti-CD8 
(YTS 169.4) or untreated. Symptoms of GVHD became obvious 6 days after reconstitution, and mortality 
started at day 8. The mutual influence of CD4+ and CD8+ T cells in the development of GVHD becomes 
apparent from our data, and demonstrates hat GVHD lethality can be caused by CDS+ T cells as well 
as by CD4+ T cells. 
Introduction 
As became clear from allogeneic bone marrow transplantation 
in animals, mature T cells in the marrow inoculum can cause 
gr~-versus-bost disease (GVHD).’ When these T cells reco- 
gnize foreign histocompatibility antigens expressed on host tis- 
sue, a systemic cellular immune response develops. Both CD4+ 
and CD8’ T cells are involved in GVHD in mice and humans, 
depending on the MHC or non-MHC differences between 
donor and recipient. We formerly demonstrated that in the 
fully allogeneic BALB/c-(C57BL x CBA)Fl strain combi- 
nation transplantation of purified CD4+ T cells induced lethal 
GVHD, whereas purified CD8+ T cells did not, suggesting a 
major role for the CD4+ T cell subset.2 
Flow cytometric analysis of T cell subsets in the spleen of 
the (C57BL x CBA)Fl recipients early after reconstitution 
demonstrated a strong increase in the number of CD4’ T cells 
peaking on day 4 or 5. Also the number of CD8+ T cells 
increased strongly, but consistently peaked l-2 days later. 
CD8’ T cells then became the predominant T cell subset. Since 
the first signs of acute GVHD became obvious 6 days after 
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reconstitution, we concluded that in this mouse strain combi- 
nation subsequent waves of CD4+ and CD8+ T cells preceded 
the development of clinically overt GVHD? 
Anti-CD4 treatment given 1 day before reconstitution was 
able to prevent the development of lethal GVHD, whereas 
anti-CD8 treatment was not. Flow cytometric analysis of the 
spleen of the recipient mice after allogeneic reconstitution and 
anti-CD4 mon~lon~ antibody (n&b) latent revealed that 
not only was the number of CD4+ T cells reduced, but also 
the number of CD8+ T cells.4 These data suggest hat by virtue 
of their interleukin 2 (IL-2) production7 the activated CD4+ T 
cells likely account for the activation and proliferation of the 
CD8+ T cells. These results do not reveal the role of the CD8+ 
T cells in the clinical symptoms of GVHD, although our find- 
ing that a strong increase in the number of CDS+ T cells pre- 
ceded the development of overt GVHD suggests that they 
are importarK 
Objective 
In this study we further investigated whether our assumption 
that CD8+ T cells do play an important role in the effector 
phase of graft-versus-host disease (GVHD) could be affirmed. 
To this end, we postponed anti-CD8 treatment to days of ongo- 
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ing GVHD and determined the effect on survival as well as 
on kinetics of T cell subset populations in the spleen by 
flow cytometry. 
Materials, methods and experimental 
design 
GVH reactions were induced in lethally irradiated (10 Gy) 
(C57BU6 x CBA/J)Fl (H-2b/k) mice by intravenous injection 
(day 0) of a mixture of 3 x 10’ BALB/c (H-2d) spleen cells 
with 6 x 106 BALB/c lymph node cells within 24 h after 
irradiation. Mice were’ treated with one optimally depleting 
dose of 200 pg or even 1 mg of highly purified rat anti-CD8 
IgG2b mAb (YTS 169.4)5*6 4 h after irradiation, but before the 
reconstitution (day -l), or on day +l, +3, +5 or +7. Anti-CD4 
treatment was performed with 1 mg of YTS 191.1,6 an IgG2b 
mAb. Mice were examined daily for the development of signs 
of acute GVHD. Mortality started at day 8. Irradiated control 
mice reconstituted with syngeneic cells survived >250 days 
without signs of disease. Radiation controls died between days 
10 and 22. 
Flow cytometric analyses of the recipient spleen cells were 
performed 4,5 and 7 days after induction of GVHD. On these 
days, cell suspensions of recipient spleens were prepared in 
buffered salt solution. Nucleated cell concentrations were 
determined with a Coulter Counter model ZBl. From these 
spleen cell suspensions (10’ nucleated cells/ml) 25 lt.1 was 
used for staining. The background staining was determined by 
staining with FITC (fluorescein isothiocyanate)-labelled rabbit 
anti-rat F(ab’), fragments alone. CD3+, CD8+ and CD4+ T cells 
were determined by direct staining with FITC-labelled KT3, 
53-6.72, and H129.19, respectively. Cells were also stained 
with a phycoerythrin-labelled Thy-l.2 mAb (30H12). Forward 
and side scatter settings were gated on leucocyte populations 
excluding red cells and debris. A total of 4000 cells was ana- 
lyzed for each determination. 
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Results 
Survival after anti-CDS treatment (200 pg) on day 
-1, +l or +3 
Postponing anti-CD8 treatment of recipients to day 3 after 
reconstitution, which is the start of the massive proliferation 
of CD4+ and CDS+ T cells, resulted in a significantly improved 
survival as compared to treatment on day -1 or day +l and 
to untreated mice (Figure 1). However, also after postponed 
anti-CD8 treatment all mice eventually died. 
Flow cytometric analys& of T cell subsets in the 
spleen after tkeatment on day -1 
After anti-CD8 treatment on day -1, low numbers of CD8+ T 
cells were found in the spleen on day 4 as well as on days 5 
and 7 compared to untreated mice (Figure 2). When mice were 
treated on day +3 similar results were obtained (Figure 3). 
Moreover, more CD4+ T cells were found on days 4, 5 and 7 
compared to untreated mice (Figure 2). In Figure 2 the indi- 
cated numbers reflect the additional CD4’ T cells above the 
control. Gn day 7 this increase in CD4+ T cells was statistically 
significant from untreated mice (P < 0.05). 
By comparing Figures 2 and 3, a difference in kinetics of 
CD4+ T cells was observed at several time points. The increase 
in CD4+ T cells occurred much more quickly in the experiment 
depicted in Figure 3. Already on day 4 a statistically signifi- 
cant increase in CD4+ T cells (7 x 106) was found as compared 
to untreated mice. 
Flow cytometric analysis of T cell subsets in the 
spleen after treatment on day +3 
After anti-CD8 treatment on day +3 very low numbers of 
CD8’ T cells were found on days 4 and 7 (Figure 3). More- 
over, fewer CD4’ T cells were found on days 4 and 7 as com- 
pared to treatment on day -1. Half the number and 0.7 times 
the number of CD4+ T cells (P < 0.05) were found on days 
4 and 7, respectively, after treatment on day +3 compared to 
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Figure 1 The effect of the moment of anti-CD8 treatment on the survival of lethally irradiated (10 Gy) (C57BJJ6 x CBA)Fl (H-29 recipients 
reconstituted with a mixture of 3 x 10’ BALBk (H-29 spleen cells and 6 x 106 BALBk lymph node cells within 24 h after irradiation. Mice were 
untreated or treated with a single dose (i.p.) of anti-CD8 IgG2b 1 day before reconstitution, or at day +1 or +3 (each group: n = 8). 
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Figure 2 FACScan analysis of CD4’ (1) and CD8+ T cells @) from 
spleen cell suspensions of (C57BU6 x CBA)Fl mice 4, 5 and 7 days 
after GVHD induction (day 0) by injection of a mixture of 3 x 10’ 
spleen cells and 6 x lo6 lymph node cells of BALBk mice (H-29. 
Similarly CD4+ and CDS’ (0) T cells were analyzed after treat- 
ment with a single dose of 200 pg of anti-CD8 IgG2b (day -1). At 
day 4, 5 and 7 we found 1.2, 5.5 and 11 x 106, respectively, more 
CD4+ T cells in anti-CD8 treated mice than in untreated mice. On day 
7 this increased number of CD4+ T cells was significantly different 
from untreated mice (P C 0.05) (n = 4 for each day and each 
treatment). 
treatment on day -1. The number of CD4+ T cells on day 
4 was comparable with that of untreated mice. A slight but 
statistically significant increase in the number of CD4+ T cells 
(P < 0.05) was seen on day 7 compared to untreated mice. 
Survival after treatment with a single high dose 
(1 mg) of anti-CD8 or anti-CD4 mAb on days -1, 
+3, +5 or +7 
Treatment of mice on days -1, +3, +5 or +7 with 1 mg of 
anti-CD8 mAb demonstrated that only after treatment on day 
+3 was there a significant improvement in survival (Figure 
4a). Moreover, treatment with this high dose of anti-CD8 rnAb 
resulted in a 60% survival at 100 days. 
Treatment of mice with a single high dose (1 mg) of anti- 
CD4 mAb on day -1 or +3 resulted in survival of all mice. 
Treatment on day +5 or +7 did not have any effect on survival 
(Figure 4b). 
Discussion 
This is a first study describing the kinetics of CD4’ and CD8+ 
T cells during the development of GVHD and the effect of 
anti-CD8 and anti-CD4 treatment on these kinetics in relation 
to the progress of the disease. We demonstrate that anti-CD8 
treatment of recipients on day 3 after reconstitution resulted 
in a significantly improved survival as compared to treatment 
on day -1 or day +l and to untreated mice (Figure 1). Treat- 
ment postponed to day +5 or +7 after transplantation, however, 
had no effect on the development of the disease (Figure 4a). 
Eventually all mice died after postponed anti-CD8 treatment 
when a dose of 200 p.g was used. This finding confirms our 
hypothesis that CD8+ T cells play an essential role in the effec- 
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Figure 3 @) FACScan analysis of spleen cell suspensions of 
(C57BU6 x CBA)Fl mice 4 and 7 days after GVHD induction (day 
0) by injection of a mixture of 3 x 10’ BALBk spleen cells and 6 x 
106 BALBk lymph node cells. Similar recipients were treated with a 
single dose of 200 pg of anti-CD8 IgG2b on day -1 or (0) on day 
+3 0. On days 4 and 7 we found 7 and 5.7 x I@, respectively, more 
CD4+ T cells in anti-CD8 day -1 treated mice compared to untreated 
mice. For anti-CD8 day +3 treated mice we found on day 4 a compara- 
ble number and, on day 7, 2.6 x 106 more CD4+ T cells compared 
to untreated mice. These differences were all statistically significant 
(P < 0.05) (n = 4 for each day and each treatment). 
tor phase, and that a beneficial effect on survival can only be 
observed when the CD8’ T cells are depleted at the start of 
the effector phase. 
Three possibilities can explain the improved survival after 
anti-CD8 treatment at day 3. Firstly, it is possible that the 
CD8+ T cells have a different role in the induction and effector 
phase of GVHD. Depletion of CD8’ T cells, therefore, could 
have a different effect on survival dependent on the moment 
of anti-CD8 treatment. Secondly, if a few CD8’ T cells 
‘escape’ the depleting effect of the mAb or if the mAb has a 
short half-life, early injection of the mAb cannot completely 
prevent the development of effector CDS’ T cells at a later 
stage. Injection of anti-CD8 rnAb 4 days later (day +3), on 
the other hand, would be expected to result in lower numbers 
of CD8+ T cells in the effector phase of GVHD. This would 
be consistent with the observed improvement in survival 
(Figure 1). Flow cytometric analyses, however, demonstrated 
that only few CD8+ T cells escaped from the depleting mAb 
(Figure 2). Moreover, after treatment on day -1 an equally 
low number of CD8’ T cells was found on days 4, 5 and 7 
(Figure 2) as in mice treated on day +3 (Figure 3). 
A third explanation is focused on the involvement of the 
CD4+ T cell. We propose that cytokines produced by CD4+ T 
cells (e.g. IL-2)’ are being consumed for activation and pro- 
liferation of CD4+ and CD8’ T cells in GVHD, but after anti- 
CD8 treatment just for CD4’ T cells alone. This is based on 
the data of Figure 2, showing more CD4+ T cells on days 4, 
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Figure 4 (a) Effect of the moment of anti-CD8 treatment and (b) effect of the moment of anti-CD4 treatment on survival. Lethally irradiated 
(C57BU6 x CBA)Fl recipients were reconstituted with a mixture of 3 x 10’ BALBk spleen cells and 6 x 106 BALBk lymph node cells within 
24 h after irradiation. Mice were untreated or treated with a single dose (i.p.) of 1 mg of mAb 4 h after irradiation and thus 1 day before reconstitution, 
or on day +3, +5 or +7 (each group: n = 5). 
5 and 7 (1.2, 5.5 and 11 x 106, respectively) after anti-CD8 In summary, CDS+ T cells do not escape from the depleting 
treatment on day -1 than in untreated mice. It is likely that effect of anti-CD8 mAb, at least not during the first 8 days 
anti-CD8 treatment on day +3 may result in a lower number after injection. Depleting the CD8+ T cells by mAb injection 
of CD4+ T cells than treatment on day -1 or day +l after shortly before reconstitution results in an increase of the num- 
reconstitution, since until then cytokines are being used for ber of CD4+ T cells. Under these conditions, the CD4+ T cells 
activation and proliferation of CD4+ T cells as well as CD8’ probably can take over the role of the CD8’ T cell in the 
T cells. Experiments were performed to test this hypothesis. effector phase of GVHD, since no difference in survival was 
These showed that after treatment on day +3 the number of observed between anti-CD8 treated (day -1 or +l) and untre.- 
CD4+ T cells was significantly lower than after treatment on ated mice. Anti-CD8 treatment on day +3 after reconstitution 
day -1 (Figure 3). Moreover, compared to untreated mice, a shortens the period for the 04’ T cells to expand. Thereby 
slight increase in the number of CD4’ T cells was seen on the role of the CD4+ T cells in the effector phase is probably 
day 7. This increase of CD4+ T cells in combination with the limited and the onset of deaths by GVHD is postponed. The 
complete absence of CD8’ T cells after treatment is probably question arises whether this postponed eath is actually caused 
insufficient to cause death at that particular moment but merely by a subsequent increase in 04” T cells or an activation of 
postpones GVH lethality (Figure 1). CD8+ T cells by CD4+ T cells once the anti-CD8 mAb is cle- 
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ared from the circulation. As treatment with a single high dose 
(1 mg) of anti-CD8 mAb resulted in 60% survival at 100 days 
(Figure 4a), we suggest that the anti-CD8 mAb prevents the 
activation of CD8+ T cells by CD4+ T cells. Thus the develop- 
ment of clinical symptoms of GVHD is limited. Together these 
data show the mutual influence of CD4+ and CD8’ T cells in 
the development of GVHD, and demonstrate that GVHD 
lethality can be caused by CD8+ T cells as well as by CD4+ 
T cells. 
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